, 56:546 | Cite as

An epidemiological analysis of monitoring of the immune status of chernobyl nuclear accident liquidators for early detection of risk groups and diagnosis of cancer diseases. Communication 1

  • I. V. Oradovskaya
  • Yu. G. Pashchenkova
  • V. V. Feoktistov
  • M. F. Nikonova
  • G. Kh. Vikulov
  • N. V. Bozheskaya
  • N. N. Smirnova
Radiobiology and Radioecology


Ionizing radiation is one of the major risk factors for cancer diseases. The question on the rate of malignant neoplasms (MNs) and their early detection in Chernobyl nuclear accident (ChNA) liquidators is still open. In this work, the results of a long-term immunological monitoring of the ChNA liquidators who live in the northwestern region of Russia have been analyzed with an attempt to detect the predictors of cancer in this population cohort. The rate of newly detected MN cases in the cohort of followup ChNA liquidators monitored in 1990–2009 was 8.856% (89 cases per 1005 persons), which is somewhat higher as compared with the average rate for the total population. As for the rate of individual MN types, lung, gastric, and prostate cancers were prevalent, which matches the worldwide trend in MN abundance. It was shown that 1-3 years before the MN diagnosis, liquidators displayed detectable changes in their immune status, including a decrease in the percentages of CD3+ and CD4+ T lymphocytes, and, to a lesser degree, B lymphocytes; a decrease in the CD4+/CD8+ ratio; increase in the relative and absolute contents of CD16+ lymphocytes; increase in the absolute CD8+ T lymphocyte counts; prevalence of CD3+16/56+ (NK-T) cells over CD3-16/56+ (NK) cells; and increase in the activity of phagocytes. The patients who displayed one or several of the listed characteristics should be ascribed to the MN risk group to be assessed for cancer markers, be more comprehensively examined, and be the subjects of dynamic observation.


immunological monitoring ionizing radiation Chernobyl nuclear accident malignant neoplasms pretumor diseases antitumor immunity special risk units 


  1. 1.
    Yu. I. Moskalev, Remote Consequences of Ionizing Radiations (Meditsina, Moscow, 1991) [in Russian].Google Scholar
  2. 2.
    Yu. I. Moskalev and V. N. Strel’tsova, Radiation Carcinogenesis in the Problem of Radiation Protection (Energoatomizdat, Moscow, 1982) [in Russian].Google Scholar
  3. 3.
    United Nation Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), Radiation Carcinogenesis in Humans (New York, 1977).Google Scholar
  4. 4.
    V. N. Strel’tsova and Yu. I. Moskalev, Blastomogenic Effect of Ionizing Radiation (Meditsina, Moscow, 1964) [in Russian].Google Scholar
  5. 5.
    A. A. Yarilin, The Action of Ionizing Radiation on Lymphocytes (Damaging and Activating Effects),” Immunologiya, No. 5, 5 (1988).Google Scholar
  6. 6.
    N. M. Berezhnaya and V. F. Chekhun, The Immunology of Malignant Growth (Naukova Dumka, Kiev, 2005) [in Russian].Google Scholar
  7. 7.
    A. M. Unni, T. Bondar, and R. Medzhitov, “Intrinsic Sensor of Oncogenic Transformation Induces a Signal for Innate Immunosurveillance,” Proc. Natl. Acad. Sci. USA 105, 1686 (2008).ADSCrossRefGoogle Scholar
  8. 8.
    R. V. Petrov and I. V. Oradovskaya, “Clinical Prelaboratory Diagnostics of the Immune Deficiency in the System of Mass Immunological Examinations of Population, in Proceedings of the All-Union Conference on Methodology, Organization, and Results of Mass Immunological Examinations, Moscow-Angarsk, 1987, p. 215.Google Scholar
  9. 9.
    R. V. Petrov, R. M. Khaitov, and I. V. Oradovskaya, “Immunological Monitoring of Large Population Groups of the Country,” Immunologiya, No. 4, 43 (1992).Google Scholar
  10. 10.
    R. V. Petrov, R. M. Khaitov, B. V. Pinegin, and I. V. Oradovskaya, “Estimation of the Immune Status in Mass Examinations: Methodological Recommendations for Researchers and Physicians, Immunologiya, No. 6, 51 (1992).Google Scholar
  11. 11.
    The State of Oncological Assistance to the Population of Russia in 2005.
  12. 12.
    M. I. Davydov and E. M. Aksel’, “Morbidity for Malignant Neoplasms in the Population of Russia and CIS Countries in 2006,” Vestn. RONTs im. N.N. Blokhina RAMN, 19(2), 52 (2008).Google Scholar
  13. 13.
    E. M. Aksel’, M. I. Davydov, and T. I. Ushakova, “Malignant Neoplasms of the Gastrointestinal Tract: Main Statistical Characteristics and Trends,” Sovr. Onkologiya 3(4), 141 (2001).Google Scholar
  14. 14.
    M. I. Davydov and M. D. Ter-Ovanesov, “Modern Strategy for Surgical Treatment of Gastric Cancer,” Sovr. Onkologiya 2(1), 4 (2000).Google Scholar
  15. 15.
    Malignant Neoplasms in St. Petersburg in 1996 (Morbidity, Mortality, Lethality, and Survival Rate), Ed. by V. M. Merabishvili (St. Petersburg, 1999) [in Russian].Google Scholar
  16. 16.
    Malignant Neoplasms in Russia in 2001, Ed. by V. I. Chissov et al. (Moscow, 2003) [in Russian].Google Scholar
  17. 17.
    G. A. Zubovskii and S. A. Khrisanfov, “Lung Cancer in people Exposed to Radiation as a Result of Chernobyl Nuclear Accident,” Vopr. Onkologii 49(3), 359 (2003).Google Scholar
  18. 18.
    L. P. Kindzel’skii and E. A. Demina, “Analysis of Morbidity in the Liquidators of Chernobyl Accident Consequences,” Vrach. Delo, No. 1, 7 (1998).Google Scholar
  19. 19.
    V. K. Ivanov, E. M. Rastopchin, A. I. Gorskii, and V. B. Ryvkin, “Oncological Morbidity among the Participants of Chernobyl Accident Cleanup,” Risk i Radiatsiya, No. 8, 65 (1996).Google Scholar
  20. 20.
    E. Ya. Sosnovskaya, in Health State of the Republic of Belarus Population that Suffered from the Chernobyl Nuclear Accident (Gomel, 2006), pp. 58–69.Google Scholar
  21. 21.
    N. B. Kholodova, E. B. Shirokova, and L. A. Zhavoronkova, “Premature Aging is Observed at a Remote Date after Small Dose Irradiation,” Vestn. Ross. Voen. Med. Akademii, No. 3, 481 (2008).Google Scholar
  22. 22.
    N. N. Kazakova, A. A. Savchenko, M. V. Yatsinov, et al., “Specific Features in the Immune Status Depending on the Stage of Gastric Cancer,” Med. Immunologiya 11(4–5), 429 (2009).Google Scholar
  23. 23.
    E. M. Aksel’ and B. P. Matveev, The State of Oncourological Diseases in Russia (Moscow, 1999) [in Russia].Google Scholar
  24. 24.
    V. P. Lazutka, Descriptive Epidemiology, Prophylactic Examinations, and Diagnostics of Early Prostate Cancer Stages in the Lithuanian SSR, Extended Abstract of Candidate’s Dissertation in Medical Sciences (Vilnius, 1987).Google Scholar
  25. 25.
    V. I. Chissov, V. V. Starinskii, and G. V. Petrova, Malignant Neoplasms in Russia in 2002 (Morbidity and Mortality) (Moscow, 2004) [in Russian].Google Scholar
  26. 26.
    V. I. Chissov, V. V. Starinskii, and G. V. Petrova, Malignant Neoplasms in Russia in 2006 (Morbidity and Mortality) (Moscow, 2008) [in Russian].Google Scholar
  27. 27.
    S. L. Parker, T. Tong, S. Bolden, et al., “Cancer Statistics, 1996,” CA Cancer. J. Clin. 65, 5 (1995).Google Scholar
  28. 28.
    H. Kato, “Cancer Mortality,” in Cancer in Atomic Bomb Survivors (Tokyo, New York, 1986), pp. 53–74.Google Scholar
  29. 29.
    V. K. Ivanov, E. V. Nilova, V. A. Efendiev, et al., “Oncoepidemiological Situation in the Kaluga Oblast of Russian Federation Ten Years after Chernobyl Catastrophe,” Vopr. Onkologii, 43(2), 143 (1997).Google Scholar
  30. 30.
    S. A. Khrisanfov, “Analysis of the Health State of the Participants of Emergency Cleanup after Chernobyl Nuclear Accident According to the Results of Work of the Russian Interagency Expert Council in 1999,” Vopr. Onkologii 46(6), 645 (2000).Google Scholar
  31. 31.
    M. R. Thomas, P. Steinberg, M. L. Votaw, and N. K. Bayne, “IgE Levels in Hodgkin’s Disease,” Ann. Allergy 37(6), 416, (1976).Google Scholar
  32. 32.
    R. Hällgren, H. Arrendal, K. Hiesche, et al., “Elevated Serum Immunoglobulin E in Bronchial Carcinoma: Its Relation to the Histology and Prognosis of the Cancer,” J. Allergy Clin. Immunol. 67(5), 398 (1981).CrossRefGoogle Scholar
  33. 33.
    E. Jensen-Jarolim, G. Achatz, M. C. Turner, et al., “AllergoOncology: the Role of IgE-Mediated Allergy in Cancer,” Allergy 63(10), 1255 (2008).CrossRefGoogle Scholar
  34. 34.
    M. Van Hemelrijck, H. Garmo, E. Binda, et al., “Immunoglobulin E and Cancer: A Meta-Analysis and a Large Swedish Cohort Study,” Cancer Causes Control 21(10), 1657 (2010).CrossRefGoogle Scholar
  35. 35.
    D. Goodale, C. Phay, W. Brown, et al., “Flow Cytometric Assessment of Monocyte Activation Markers and Circulating Endothelial Cells in Patients with Localized or Metastatic Breast Cancer,” Cytometry B Clin. Cytom. 76(2), 107 (2009).Google Scholar
  36. 36.
    Holland-Frei Cancer Medicine, Ed. by D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, et al., (BC Decker, 2003).*.
  37. 37.
    T. Arai, T. Kuroishi, Y. Saito, Y. Kurita, et al., “Tumor Doubling Time and Prognosis in Lung Cancer Patients: Evaluation from Chest Films and Clinical Followup Study. Japanese Lung Cancer Screening Research Group,” Jpn. J. Clin. Oncol. 24(4), 199 (1994).Google Scholar
  38. 38.
    M. Akiyama, “Late Effects of Radiation on the Human Immune System: An Overview of Immune Response among the Atomic-Bomb Survivors,” Int. J. Radiat. Biol. 68(5), 497 (1995).CrossRefGoogle Scholar
  39. 39.
    Y. Kusunoki and T. Hayashi, “Long-lasting Alterations of the Immune System by Ionizing Radiation Exposure: Implications for Disease Development among Atomic Bomb Survivors,” Int. J. Radiat. Biol. 84(1), 1 (2008).CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2011

Authors and Affiliations

  • I. V. Oradovskaya
    • 1
    • 2
  • Yu. G. Pashchenkova
    • 1
    • 2
  • V. V. Feoktistov
    • 1
    • 2
  • M. F. Nikonova
    • 1
    • 2
  • G. Kh. Vikulov
    • 1
    • 2
  • N. V. Bozheskaya
    • 1
    • 2
  • N. N. Smirnova
    • 1
    • 2
  1. 1.Institute of ImmunologyFederal Medical Biology AgencyMoscowRussia
  2. 2.Central Medical Sanitary Station no. 38Sosnovyi Bor, Leningrad oblastRussia

Personalised recommendations